Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 308

1.

Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.

Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S.

J Thorac Oncol. 2012 Jan;7(1):105-14. doi: 10.1097/JTO.0b013e3182352a45.

PMID:
22134068
[PubMed - indexed for MEDLINE]
2.

Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Sun JM, Han J, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8.

PMID:
21716147
[PubMed - indexed for MEDLINE]
3.

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

Kasai D, Ozasa H, Oguri T, Miyazaki M, Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K, Niimi A.

Anticancer Res. 2013 May;33(5):1935-40.

PMID:
23645741
[PubMed - indexed for MEDLINE]
4.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

Ranson M, Reck M, Anthoney A, Hanauske AR, Dean E, Melezinek I, Klingelschmitt G, Kletzl H, Blatter J, Twelves C.

Ann Oncol. 2010 Nov;21(11):2233-9. doi: 10.1093/annonc/mdq246. Epub 2010 May 5.

PMID:
20444843
[PubMed - indexed for MEDLINE]
Free Article
5.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.

PMID:
23242435
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
[PubMed - indexed for MEDLINE]
Free Article
7.

Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2003 Apr;94(4):394-9.

PMID:
12824911
[PubMed - indexed for MEDLINE]
8.

Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.

Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko JL.

J Thorac Oncol. 2010 Aug;5(8):1143-51. doi: 10.1097/JTO.0b013e3181e0b954.

PMID:
20559153
[PubMed - indexed for MEDLINE]
9.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

PMID:
18927285
[PubMed - indexed for MEDLINE]
Free Article
10.

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC.

J Thorac Oncol. 2011 Apr;6(4):774-80. doi: 10.1097/JTO.0b013e31820cf053.

PMID:
21336183
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.

Grabauskiene S, Bergeron EJ, Chen G, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM.

J Surg Res. 2014 Mar;187(1):6-13. doi: 10.1016/j.jss.2013.12.016. Epub 2013 Dec 18.

PMID:
24418519
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II.

J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

PMID:
22729036
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].

Chen XX, Zhou CC.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):570-2. doi: 10.3760/cma.j.issn.0529-5807.2012.08.017. Chinese. No abstract available.

PMID:
23157756
[PubMed - indexed for MEDLINE]
14.

A decade of advances in treatment for advanced non-small cell lung cancer.

Gettinger S, Lynch T.

Clin Chest Med. 2011 Dec;32(4):839-51. doi: 10.1016/j.ccm.2011.08.017. Review.

PMID:
22054890
[PubMed - indexed for MEDLINE]
15.

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review.

PMID:
24067998
[PubMed - indexed for MEDLINE]
16.

Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.

Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, Hashimoto S.

Anticancer Res. 2012 Oct;32(10):4589-96.

PMID:
23060591
[PubMed - indexed for MEDLINE]
17.

P63 expression in lung carcinoma: a tissue microarray study of 408 cases.

Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7.

PMID:
15551738
[PubMed - indexed for MEDLINE]
18.

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ.

J Thorac Oncol. 2011 Sep;6(9):1474-80. doi: 10.1097/JTO.0b013e3182208fc2.

PMID:
21642865
[PubMed - indexed for MEDLINE]
19.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
[PubMed - indexed for MEDLINE]
20.

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.

Mol Pharmacol. 2008 Apr;73(4):1290-300. doi: 10.1124/mol.107.042382. Epub 2008 Jan 10.

PMID:
18187583
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk